☆ 4.7 Letter

Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis et al

ANNALS OF THE RHEUMATIC DISEASES (2022)

Get Full Text
Add to Collection

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 81, Issue 12, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2020-218942

Keywords

biological therapy; familial Mediterranean fever; outcome assessment; health care

Categories

Rheumatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.